Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2012-02-20 Legal Proceedings Report
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Conclusion of second patent infringement suit 2 pages 121.0KB
Legal Proceedings Report Classification · 95% confidence The document is an ASX announcement dated February 21, 2012, regarding the successful conclusion of a patent infringement suit and settlement by Genetic Technologies Limited. It discusses legal matters related to patent assertion suits and settlements, including references to ongoing litigation and licensing revenue. There are no financial statements, earnings data, or management discussion of financial results. The content focuses on legal proceedings and updates on patent litigation outcomes. Therefore, this document fits best under the category of Legal Proceedings Report (LTR). The document length is 5532 characters, which is sufficient for a substantive announcement rather than a brief notice or report publication announcement.
2012-02-20 English
GTG receives CLIA Certificate of Compliance 2 pages 132.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated February 16, 2012, regarding Genetic Technologies receiving a CLIA Certificate of Compliance from the Centers for Medicare and Medicaid Services (CMS) in the USA. It discusses regulatory compliance and market entry milestones for the company's BREVAGen™ test in various U.S. states. The content is a corporate announcement about regulatory certification and market expansion, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. The document is longer than 5,000 characters but is clearly an announcement of a regulatory milestone and business update. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2012-02-15 English
Settlement with Eurofins STA 2 pages 120.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated February 6, 2012, reporting the execution of a Settlement and License Agreement between Genetic Technologies Limited and Eurofins STA Laboratories, Inc. It discusses the settlement of a patent assertion suit and ongoing discussions with other parties. The document does not contain financial statements, quarterly or annual results, nor does it present detailed management discussion or governance information. It is a corporate announcement about a legal settlement and licensing agreement, which does not fit into categories like Annual Report, Interim Report, Earnings Release, or Legal Proceedings Report (which would require more detailed legal case information). It is not a report publication announcement or certification. The content aligns best with a general regulatory announcement about a material corporate event, which fits the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2012-02-05 English
Forfeiture of options 1 page 36.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated February 6, 2012, regarding the forfeiture and cancellation of options previously issued to a former employee. It provides specific details about the options forfeited, including the number, exercise price, and expiry date. The content is a brief announcement about a change in option holdings and does not contain financial statements, management discussion, or detailed financial data. It is not a report, earnings release, or regulatory certification. The document fits best into a category related to capital or financing updates, as it concerns changes in option holdings which affect the company's capital structure. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short and focused on this specific update, supporting this classification with high confidence.
2012-02-05 English
In memoriam Dr. Malcolm Simons 2 pages 121.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated February 2, 2012, expressing condolences on the passing of Dr. Malcolm Simons, a co-founder of Genetic Technologies Limited. It contains no financial data, no discussion of financial results, no regulatory filings, no voting results, no management changes, no capital or financing updates, and no other report or presentation content. It is a corporate announcement related to a personnel event (in memoriam) rather than a formal report or regulatory filing. The document length is 4909 characters, which is short and consistent with an announcement rather than a detailed report. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2012-02-01 English
Appendix 4C - quarterly 10 pages 107.9KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 31 December 2011'. It contains detailed operational updates, financial cash flow statements for the quarter and half-year, corporate matters including director appointments and resignations, and licensing and R&D activities. The presence of actual financial data such as consolidated cash flow statements and operational metrics for the quarter indicates this is a comprehensive interim financial report. The document is approximately 15,000 characters long, which is consistent with a substantive report rather than a brief announcement. The quarterly period ending 31 December 2011 is explicitly stated, and the document includes financial and operational analysis typical of an Interim / Quarterly Report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2012
2012-01-29 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.